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Abstract
Background: The most common management strategy for tinnitus provided in the UK audiology clinics is
education and advice. This may also be combined with some form of sound therapy (e.g. digital hearing aids).
While education and advice is generally provided by all clinics, there is a marked variability in provision of hearing
aids that depends very much on clinical decisions. A recent Cochrane review concluded a lack of evidence to
support or refute hearing aid use as a routine intervention for people with tinnitus and hearing loss. This lack of
evidence is reflected in the inconsistency of tinnitus management in the UK. The aim of the HUSH trial is to
determine the feasibility of conducting a definitive randomised controlled trial (RCT) of the effectiveness and cost-
effectiveness of hearing aids for adults with tinnitus and hearing loss.
Methods: This is a multicentre randomised controlled feasibility trial. Up to 100 adults, aged 18 and over,
presenting to 5 UK audiology clinics with a complaint of tinnitus and measurable hearing loss are being
randomised to receive either (i) education and advice (treatment as usual) or (ii) education and advice with digital
hearing aids. Feasibility outcomes are being collected around recruitment, retention, patient and healthcare
professional acceptability and clinical outcome assessment. Outcomes are being collected via postal questionnaire
at 12 weeks post baseline. A nested interview study will supplement clinical and other outcome data, providing a
detailed understanding of participants’ and audiologists’ experience of both tinnitus management and the research
processes.
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Discussion: This feasibility trial will help us to (i) determine if it is feasible to conduct a multicentre RCT comparing
treatment as usual and treatment as usual plus digital hearing aids; (ii) optimise the design of a future definitive,
multicentre RCT; and (iii) inform which outcome(s) is/are relevant for patients. This work presents an important first
step in determining the effectiveness of hearing aids as a tinnitus management strategy.
Trial registration: ISRCTN, ISRCTN14218416. Registered on 30 July 2018.
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Background
Tinnitus is defined as the perception of sound in the ab-
sence of an external source [1]. It is typically described
by those who experience it as a ringing, hissing, buzzing
or whooshing sound and is thought to result from ab-
normal neural activity at some point or points in the
auditory pathway, which is erroneously interpreted by
the brain as sound.
Tinnitus is a major problem. When defined as lasting
for more than 5 min at a time, it has been shown to
affect 12–30% of the adult population, with 3 to 31%
reporting bothersome tinnitus [2]. Age and hearing loss
are both known pre-disposing factors. For example, the
incidence of clinically bothersome tinnitus rises with in-
creasing age [3], and it is estimated that tinnitus preva-
lence in people with hearing loss may reach 70–85% [4–
6]. Many people with tinnitus experience symptoms that
negatively affect the quality of life (including sleep dis-
turbances, hearing difficulties, difficulties with concen-
tration, social isolation and emotional difficulties
including anxiety, depression, irritation or stress) and re-
quire clinical intervention [5].
Tinnitus represents a significant burden on healthcare
services. In England, it is estimated that there are ¾ mil-
lion primary care consultations per year with a primary
complaint of tinnitus [7]. In the UK, care pathways in-
clude appointments with Ear Nose and Throat (ENT)
and audiology specialists (in all combinations) [8]. Yet,
currently, there are no National Institute for Health and
Care Excellence (NICE) clinical guidelines for the man-
agement of tinnitus. The Department of Health Good
Practice Guide [9] does provide some guidance on the
commissioning of tinnitus services in the National
Health Service (NHS). However, this is not evidence-
based and it lacks specific recommendations on the
provision of hearing aids for patients with tinnitus and
hearing loss.
In the UK, the most common management strategy is
education and advice. This typically includes, but is not
limited to, explanations of tinnitus and its association
with hearing loss, education about lifestyle factors that
may have positive or negative effects on tinnitus, and a
description of available management strategies [10].
Some audiologists may also combine education and
advice with some form of sound therapy, which is the
provision of electronic devices to amplify external
sounds (e.g. hearing aids) or to produce sounds for
therapeutic use (e.g. sound generators) [9]. While educa-
tion and advice is generally provided by all clinics, there
is a marked variability in the provision of devices (i.e.
hearing aids) that depends very much on local or indi-
vidual clinical decisions [11].
The primary function of a digital hearing aid is to
amplify and modulate sound to make the sound more
accessible and to aid communication. Using hearing aids
in tinnitus management has been proposed as a useful
strategy since the 1940s [12], although the benefit re-
portedly varies and there is no clear consensus on when
a person would or would not benefit from amplification
[13, 14]. A number of ways in which hearing aids may
be beneficial for tinnitus have been suggested [15]. Hear-
ing aids can amplify environmental sounds and mask or
provide a distraction from tinnitus. They can reduce lis-
tening effort and improve communication, which in turn
can reduce the stress and anxiety commonly associated
with tinnitus. Other possible mechanisms include
physiological effects on tinnitus-related brain activity by
‘recalibrating central gain’ or preventing maladaptive
plastic changes in the brain related to hearing loss. Al-
ternatively, amplification may simply refocus attention
on alternative auditory stimuli that are incompatible and
unrelated to the tinnitus sound.
Despite these findings, there is no robust evidence that
shows that hearing aids are more effective in alleviating
tinnitus than education and advice alone. The Cochrane
review of sound therapy for the management of tinnitus
looked at the quality of current evidence of effectiveness
of different forms of sound therapy for tinnitus [15].
There was no evidence to support the superiority of any
form of sound therapy (including hearing aids) for tin-
nitus over waiting list control, placebo or education/in-
formation with no device. The review concluded that
there is a lack of evidence to support or refute hearing
aid use as a routine intervention for people with tinnitus
and hearing loss. It called for further research to gener-
ate high-quality evidence for the effectiveness of differ-
ent sound therapy options (including hearing aids) using
rigorous methodology.
Haines et al. Pilot and Feasibility Studies            (2020) 6:41 Page 2 of 9
In line with the above, there is no standard care path-
way for patients presenting with a complaint of tinnitus.
Decisions are influenced by the experiences or personal
opinions of individual audiologists, such that patients
currently get different care depending on which audiolo-
gist they see. A European review of clinical guidelines
observed that differences include recommendations for
sound therapy as a form of treatment for tinnitus dis-
tress [16]. A survey of UK audiology departments has
shown that half of the clinicians have different candidacy
criteria for fitting hearing aids for patients with and
without tinnitus [11, 13, 17]. Patients with mild hearing
loss and tinnitus are less likely to receive hearing aids as
are those who do not report hearing difficulties, despite
the fact that tinnitus annoyance can be as debilitating in
people who have mild or more severe hearing loss as in
those who do not report hearing difficulties [18–20].
Evaluating the effectiveness of digital hearing aids for
tinnitus relief is known to be a priority research question
for clinicians and patients as this was identified in the
top ten outcomes from a James Lind Alliance (JLA) Tin-
nitus Priority Setting Partnership [21].
The overarching objective of the present trial is to in-
vestigate the feasibility and acceptability of conducting a
randomised controlled trial (RCT) comparing (i) educa-
tion and advice (Treatment as Usual (TAU)) and (ii)
TAU plus digital hearing aids, for the management of
people with tinnitus and hearing loss.
To achieve this, objectives around recruitment, out-
come assessment and acceptability have been defined.
Addressing these objectives will (i) determine if it is feas-
ible to conduct a multicentre RCT comparing TAU and
TAU plus digital hearing aids; (ii) help to optimise the
design of a future definitive, multicentre RCT; and (iii)
inform which outcome(s) is/are most relevant for pa-
tients to guide the selection of a primary outcome for
the definitive RCT.
Methods
This trial is an open-label, two-arm, multicentre, rando-
mised controlled feasibility trial with an economic evalu-
ation and a nested interview study (Fig. 1).
Setting and participants
Five NHS audiology departments representing a range of
clinical settings and service sizes are recruiting to the
trial. The participants are adults, aged 18 and over, pre-
senting to the audiology clinic with a primary complaint
of tinnitus. Depending on local care pathways, partici-
pants may have been referred by their GP or an ENT de-
partment. All participants must be willing to provide
written informed consent and have a clinical diagnosis
of tinnitus, with hearing loss, as defined by the assessing
audiologist. Potential participants will be excluded on
the basis of the following: tinnitus of a medically treat-
able origin, inability to communicate in written English,
having started or stopped medication for anxiety/depres-
sion within the last 3 months, previous use of a hearing
aid in the last 12 months or current use of any combin-
ation device or behind the ear sound generator. A com-
bination device is a digital hearing aid that also
functions as a sound generator.
Intervention
Both groups receive TAU, which, depending on local
practice, may consist of any combination of the follow-
ing: explanations of tinnitus and its association with
hearing loss, education about lifestyle factors that may
have positive and negative effects on tinnitus and ex-
planation of available management strategies and differ-
ent levels of counselling depending on patient need. For
the purposes of the trial, TAU must not include the pre-
scription of any combination device or at-ear sound gen-
erator and, for the control arm, must not include the
provision of hearing aids.
In addition to TAU, the intervention group is also fit-
ted with a digital hearing aid according to standard pro-
cedure. The hearing aid used must be CE marked and
approved for use in the NHS and by local site for its
intended purpose. The fitting audiologist should make a
clinically appropriate daily usage recommendation,
which is recorded by the audiologist using pre-defined
categories (< 1 h per day, ≥ 1 to < 4 h per day, ≥ 4 to <
8 h per day, ≥ 8 h per day). Adherence is checked by
comparing participant reported usage at 12 weeks to the
audiologist recommended usage.
Outcomes
Outcomes for the feasibility trial have been separated
into those that determine the feasibility and acceptability
of a large definitive trial and patient-reported outcome
measures (PROMs). As the core outcome set for tinnitus
is still under development [22, 23], there is no consensus
on which PROM should be used as the primary outcome
in a definitive trial. Therefore, in this feasibility trial, a
range of PROMs have been used to inform the choice of
the primary outcome for the definitive trial.
Feasibility outcomes
• Recruitment: Outcomes to assess whether it would be
possible to recruit to a definitive trial.
▪ Proportion of patients eligible for the trial, patient
and clinician views of the treatment options and
barriers to screening and recruitment, number and
proportion of patients recruited and randomised,
characteristics of recruited patients, hearing aid
adherence, trial retention, completeness of the
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collected data, components of TAU used across sites,
hearing aid fitting parameters, mechanisms to capture
re-referral rates.
• Acceptability: Outcomes to assess whether partici-
pants and clinicians would find the interventions
and trial design acceptable.
▪ Feedback from participants and clinicians regarding
experience with the trial (e.g. conduct, design,
treatments) and opinions of the intervention.
▪ Hearing aid adherence
• Outcome assessment: Outcomes to help identify the
most appropriate primary outcome for a definitive
trial.
• Participant opinion of relevance of self-reported out-
come measures; Distribution of patient-reported out-
come measures; estimation of clinically important
differences
• Safety: Capturing exacerbation of symptoms and ad-
verse event monitoring to assess the feasibility of
safety data capture for a definitive trial.
• Healthcare resource use questionnaire to assess the
feasibility of capturing health economic data
Patient-reported outcome measures
All PROMS are collected at baseline and 12 weeks to meas-
ure changes between the two time points in the following:
• Tinnitus symptom severity, measured with the Tin-
nitus Functional Index (TFI) [24]
Fig. 1 Flowchart indicating participant flow through the trial
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• Effects of hearing impairment on emotional and so-
cial adjustment, measured with the Hearing Handi-
cap Inventory for the Elderly (HHIE) [25]
• General health status and health-related quality of
life, measured with the Health Utilities Index Mark
3 (HUI3) [26]
• Depression and anxiety, measured with the Hospital
Anxiety and Depression Scale (HADS) [27]
• The outcomes that the patient considers the most
important on one or two symptoms related to tin-
nitus that they are seeking help with, measured with
the Measure Yourself Medical Outcome Profile
(MYMOP2) [28]
• Health-related quality of life, measured with the EQ-
5D-5L [29]
• Participant-reported improvement in tinnitus and
hearing (Global Rating of Change Score): measuring
participant reported change in tinnitus using a 7-
point Likert scale to the questions: (1) All things
considered, how is your overall tinnitus condition
now, compared to 3 months ago? (2) All things con-
sidered, how is your overall hearing now, compared
to 3 months ago? For both questions, response op-
tions are ‘much improved’, ‘moderately improved’,
‘slightly improved’, ‘no change’, ‘slightly worse’,
‘moderately worse’ or ‘much worse’.
Randomisation allocation, concealment and blinding
Randomisation (1:1 ratio) to the two trial arms uses a
minimisation algorithm, minimising by trial site, tinnitus
symptom severity and degree of hearing loss. Tinnitus
symptom severity is categorised on three levels informed
by TFI data acquired in the baseline clinic appointment
(mild 0–28, moderate 29–65, severe ≥ 66 [30]), and the
degree of hearing loss is categorised on two levels based
on pure tone average of air-conduction thresholds at 0.5,
1, 2, 4, 6 and 8 kHz (≤ 40 dB, > 40 dB), measured no
more than 6 months prior to the date of randomisation.
Study procedures
Potential participants are screened from upcoming tin-
nitus clinic lists and the participant information sheet is
sent in the post. Further eligibility screening takes place
at the beginning of the routine care appointment, and
the audiologist approaches the patient during their clinic
visit if they are eligible for the trial. If written informed
consent is provided after speaking further with the audi-
ologist, site staff randomise the individual participant via
a secure Web-based electronic randomisation system de-
veloped and maintained by the Nottingham Clinical Tri-
als Unit (NCTU). Allocation determines which
treatment(s) the clinician proceeds to offer the partici-
pant during the routine care appointment. If the partici-
pant is randomised to the intervention arm, the hearing
aid may be fitted at a separate appointment (up to 4
weeks post randomisation).
During the 12-week treatment phase, participants may
withdraw from the trial intervention but remain in the
trial for the purpose of providing follow-up data only.
All participants receive a questionnaire pack in the mail
at 12 weeks post randomisation for the collection of trial
outcomes. Participants have a 1-month window to re-
turn the completed questionnaire. To maximise reten-
tion, trial management staff start to chase non-
completed questionnaires around 2 weeks after first
sending. Questionnaire reminders are communicated to
participants via post, email, text and telephone. Trial
participants re-integrate the local standard care pathway
upon conclusion of their involvement in the trial and
may request to be reassessed at that time by their local
clinic.
The structure of the trial and the timing of enrolment
and assessments are detailed in Table 1. Audiometry
and TFI must be collected prior to randomisation to en-
able stratification.
Blinding
Blinding of treatment allocation is not possible for the
clinician or the participant, as hearing aids are offered
only to the intervention group. The trial statistician,
health economist and chief investigator are blinded to all
treatment allocations. The trial management staff are
also unblinded to treatment allocation in order to send
out the appropriate version of the 12-week follow-up
questionnaire.
Data collection and management
All data and participant contact details are treated confi-
dentially and held on two separate secure University of
Nottingham servers with restricted and password-
protected access. Data checks are undertaken in line
with the data management plan, and the manual entry
of all audiogram data is centrally crosschecked with a
screenshot of the audiograms to ensure accurate entry.
Regular central monitoring activities are undertaken
by the NCTU, and sites are monitored in accordance
with the data monitoring plan. Audits will take place at
the request of the sponsor or regulatory authorities.
Sample size
Since this is a feasibility trial, a formal calculation was
not appropriate. The trial aims to randomise 100 partici-
pants over 12 months from five recruiting centres to ex-
plore feasibility parameters such as methods of
recruitment and recruitment and retention rates in dif-
ferent types of centres. This sample size will enable esti-
mation of a retention rate of greater than 80% to within
8% points of the true value with 95% confidence.
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Together with information from qualitative interviews
and the information collected about PROMs which will
inform the primary outcome and sample size for a future
trial, this should provide sufficient to determine feasibil-
ity for a future definitive trial.
Planned analyses
For this feasibility trial, there are no stopping rules de-
fined or formal interim analysis planned. The planned
final analysis will take place when all data relating to all
outcomes have been collected, the database has been
locked and the treatment codes revealed.
The analysis and reporting of the trial will be in ac-
cordance with the Consolidated Standards of Reporting
Trials (CONSORT) [31] and the CONSORT extension
for randomised pilot and feasibility trials [32]. A full
statistical analysis plan (SAP) will be developed and fina-
lised prior to database lock. Following the CONSORT
guidelines, a flow diagram showing the numbers of
people referred, approached and screened, eligible,
consented and randomised (with reasons for exclusions)
will be produced.
Recruitment rates at sites will be summarised using
appropriate statistics. Completeness of data collection at
baseline and 12 weeks will be summarised by trial arms.
Descriptive summaries of outcome data at baseline and
12 weeks will be presented. Formal statistical testing for
between-arm comparisons will not be performed; how-
ever, differences between arms may be presented with
95% confidence intervals where appropriate. The num-
ber and proportion of participants who underwent each
allocated procedure will also be summarised by trial
arms.
Analyses for selection of potential primary outcome
Investigation of PROMs will be performed independ-
ently of the treatment group. The total scores at baseline
and 12 weeks will be summarised for the five PROMs
(TFI, HHIE, HUI3, HADS and MYMOP2) listed in the
‘Patient-reported outcome measures’ section. The
Table 1 Summary of assessments
Trial period
Baseline 12-week follow-up Participant interviews (within 1 month of follow-up completion)
Enrolment
Eligibility screen X
Informed consent X
Randomisation X
Assessments
Baseline characteristics X
Audiometry aX
Hearing aid specification bX
Hearing aid fitting cX
TFI X X
HHIE X X
HUI3 X X
HADS X X
MYMOP2 X X
EQ-5D-5L X X
Healthcare resource use X X
Hearing aid adherence X X
Safety reporting X
Global rating of change score X
Experience of tinnitus management Xde
Experience of research process Xde
aHearing thresholds measured no more than 6 months prior to baseline may be reused
bFor those randomised to receive a hearing aid
cMay take place at baseline or at a second fitting appointment. Fitting should take place ideally within 2 weeks up to a maximum of four from the time of the
first visit
dA subset of participants and audiologists only
eFor patients who consent to taking part in the interviews only, interviews for those selected will take place within 1 month of consent. Audiologist interviews will
take place towards the end of the recruitment period of the trial
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change from baseline for PROM scores will be calculated
and summarised at 12 weeks.
A global improvement question will be answered at 12
weeks. PROM scores for participants who answered
“slightly improved” or “moderately improved” will be
used as an anchor to investigate the smallest difference
that the participants perceive to be beneficial.
Minimum clinically important effects for each PROM
will be estimated using three anchor-based responsive-
ness statistics: (i) standardised response mean (SRM), (ii)
effect size (ES) and (iii) Guyatt’s Responsiveness Index
(GRI). This analysis, along with patients’ views on the
relevance of PROMs to their tinnitus (captured as a part
of the questionnaires and nested interviews), will guide
the choice of relevant PROMs for use in a definitive trial
of treatment of tinnitus.
Economic evaluation
An exercise in health economic evaluation is being under-
taken in the trial. The objectives of this work are to (i) de-
termine whether key resource use and health-related
quality of life (HRQoL) can be obtained from data collected
remotely from participants, (ii) identify unit costs from sec-
ondary sources to attach to the resource use, (iii) design
and test a cost pro forma for participants to complete, (iv)
execute the steps necessary for a cost-utility analysis to de-
termine whether TAU combined with digital hearing aids is
likely to produce a feasible cost-effectiveness analysis and
(v) explore the variables that indicate uncertainty.
The economic evaluation will explore the feasibility of
collecting HRQoL and resource use data. The HUI3 was
administered before and after the intervention for the
calculation of HRQoL.
Data analysis for a preliminary cost analysis will be
performed to explore incremental cost differences be-
tween the two trial arms. Quality-adjusted life-years
(QALYs) with available data will be determined using
the ‘area under the curve’ approach. This data will be ex-
plored in relation to costs.
Stakeholder interview study
A nested interview study is being conducted alongside
the feasibility trial. The purpose of this study is to (i) as-
sess feasibility and acceptability of trial processes, (ii) as-
sess feasibility and acceptability of the intervention (for
both participants and clinicians) and (iii) to consider
patient-reported outcome from the perspective of trial
participants. Information will be gathered in a series of
semi-structured interviews, which will be undertaken
face-to-face or via telephone depending on the partici-
pants’ preference. Trial participants will consent separ-
ately for the interview study.
Approximately 30 participants will be interviewed after
their 12-week treatment period has passed. Participants
will be selected purposively to capture a range of different
experiences and treatment outcomes. A small number of
interviews (n < 10) will also be carried out with those who
declined to take part in the trial to explore barriers to re-
cruitment. These interviews will take place within 1
month of being approached about trial participation. After
recruitment activities have ceased, approximately 10 clin-
ical staff will be interviewed to review their experience of
the trial in terms of participant recruitment and integrat-
ing the research within clinical care.
With the participants’ consent, data will be recorded
and transcribed in full. Otherwise, written notes will be
used. All interview data will be analysed using a frame-
work approach [33, 34]. Data analysis will be supported
by lay members of the research group, and output from
the data analysis will be used to generate recommenda-
tions for the subsequent definitive trial.
Trial oversight
Oversight is provided by the Trial Steering Committee
(TSC) which comprises an independent chair and two in-
dependent members (including one patient representa-
tive). The TSC will also contribute to the final assessment
for feasibility. Further details can be found in the acknowl-
edgements. A separate data monitoring committee is not
required due to the very low risk associated with the inter-
vention; this function is be covered by the TSC.
Assessment of feasibility
There are few examples of multi-centre RCTs in UK
audiology clinics on which to inform the setting of pre-
defined thresholds for specific feasibility outcomes.
Upon the recommendation of the TSC, an adaptation of
the feasibility assessment proposed by Thyer et al. [35]
will be used to determine whether a fully powered ran-
domised trial will be feasible. This will be assessed using
both the quantitative and qualitative data gathered
within the context of the present trial.
The feasibility study will be deemed successful if:
1. Eighty per cent of recruitment target is achieved.
2. Number of sites retained, number of site achieving
recruitment target, study consent and retention
rates and proposed sample sizes, indicate delivery of
the full RCT is plausible within a 5-year study
period.
3. Participants and clinicians report acceptability of the trial.
The Trial Management Group and TSC will consider the
above criteria, resulting in one of the following outcomes:
1. Stop: definitive RCT not feasible;
2. Go: optimise design based on feasibility findings;
apply for funding of a definitive RCT.
Haines et al. Pilot and Feasibility Studies            (2020) 6:41 Page 7 of 9
Discussion
Without a standard care pathway across the UK for the
management of tinnitus, we have chosen to undertake a
feasibility trial to inform the design of a future definitive
RCT to assess the effectiveness and cost-effectiveness of
digital hearing aids in patients with tinnitus and hearing
loss. We anticipate that this trial might present a num-
ber of methodological challenges as there have been
relatively few previous large-scale RCTs engaging audiol-
ogists within UK audiology clinics; at least one large-
scale RCT (of an investigational medicinal product) has
reported the need to adjust procedures, recruitment and
screening methods to meet targets [36]. Work still needs
to be undertaken to help audiology clinics embed high-
quality trials alongside their clinical practice. This
present feasibility trial is a further step towards strength-
ening the culture of RCT research within this group of
healthcare professionals.
The outcomes of this trial will provide the Trial
Management Group and Trial Steering Committee with
the data to determine if it is feasible to conduct a multi-
centre RCT comparing TAU and TAU plus digital hearing
aids and to inform the best design of this future definitive
RCT. This trial will also help to refine which outcomes
would be most suitable for the definitive trial, and import-
antly to define which of the existing outcome instruments
is most relevant to patients, and as such should be used as
the primary outcome. This work is being carried out
alongside work to define a core outcome set for early-
phase clinical trials of sound-based interventions for
chronic subjective tinnitus in adults [22, 23].
If the present trial shows that a definitive trial is feas-
ible, the data gathered in the future trial can ultimately
be used to facilitate evidence-based NHS commissioning
and clinical practice in audiology and to ensure that
provision of hearing aids for tinnitus will be informed by
high-quality research evidence promoting equal access
to management options and current technology for all
tinnitus patients. We see the HUSH Feasibility Trial as
an essential and valuable methodological step towards
future research that will provide the needed evidence
base for the clinical efficacy and cost-effectiveness of
hearing aids as a tinnitus management strategy.
Current trial status
Protocol version 1.2 4 September 2018. Recruitment
opened on 15 October 2018 and will continue for a
period of 12 months.
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